Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.

Status: Completed

Protocol number: NV20236

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: An open-label multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in children.

Brief summary: This study will evaluate the safety of Tamiflu, when used for the prevention of influenza in children during the flu season. Children who would benefit from influenza prophylaxis when influenza is circulating in the community will receive treatment with Tamiflu syrup (or capsules) 30mg-75mg once daily (dependent on body weight) for 6 weeks. Safety data and influenza symptoms will be recorded throughout the study. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals. Target sample size is 50.

Study phase: IV

Study type: Interventional; Prevention; Non-Randomized; Open Label; Uncontrolled; Single Group; Safety/Efficacy study

Condition: Influenza

Intervention type: Drug

Intervention name: oseltamivir [Tamiflu]

Primary outcome: 1. AEs, laboratory parameters, vital signs. Time frame: Throughout study 2. Percentage of patients with laboratory confirmed clinical influenza Time frame: Throughout study

Key secondary outcomes: 1. Percentage of subjects with asymptomatic influenza; percentage with an influenza-like illness. Time frame: Throughout study

Inclusion criteria:

  • males or females, 1-12 years of age;
  • candidate for seasonal prophylaxis;
  • negative rapid diagnostic test for influenza at baseline.

Exclusion criteria:

  • symptoms suggestive of influenza-like illness;
  • positive rapid diagnostic test for influenza;
  • antiviral treatment for influenza in 2 weeks prior to randomization.

Gender: Males or Females

Age limits: Min: 1 year Years Max: 12 Years

Accepts healthy volunteers: No

Trial registration date: 12/18/2006

Date last updated: 8/29/2008


Link to trial result

This trial was conducted at the following locations:

Canada

  • Coquitlam, BC

United States

  • West Palm Beach, FL
  • Pittsburgh, PA
  • Jackson, TN

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply